PATENT CLAIM ANALYSIS

Application Number: 16150070
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-01
Patent Classification: ["514", "210200"]

Abstract:
The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables R A , R AA , subscript n, subscript q, ring A, X 2 , L, subscript m, X 1 , R 1 , R 2 , R 3 , R 4 , R 5 , D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Claim (Index 2):
The compound or pharmaceutically acceptable salt of  claim 1 , which is a compound of Formula (II): or a pharmaceutically acceptable salt thereof, wherein: R o  is hydrogen or C 1-6  alkyl; R 1  and R 2  are each independently selected from the group consisting of hydrogen, \u2014CN, \u2014F, \u2014Cl, \u2014Br, \u2014I, C 1-8  alkyl, C 1-8  haloalkyl, C 1-8  heteroalkyl, C 3-8  cycloalkyl-C 1-6  alkyl, C 2-7  heterocycloalkyl-C 1-6  alkyl, wherein said R 1  and R 2  substituents are independently optionally substituted with 1-3 R 1/2  substituents selected from the group consisting of F, Cl, Br, I, \u2014CN, \u2014OH, \u2014NH 2 , \u2014NO 2 , C 1-6  alkyl, C 1-8  haloalkyl, C 1-8  alkoxy, C 1-8  alkylthio, C 1-8  alkylamino and C 1-8  dialkylamino; or R 1  and R 2  are combined to form a 3- to 7-membered carbocycle or heterocycle ring comprising 1 to 2 heteroatoms selected from N, O and S, and wherein said carbocycle or heterocycle ring are optionally substituted with 1 to 3 R 1/2  substituents selected from the group consisting of F, Cl, Br, I, \u2014CN, \u2014OH, \u2014NH 2 , \u2014NO 2 , C 1-6  alkyl, C 1-8  haloalkyl, C 1-8  alkoxy, C 1-8  alkylthio, C 1-8  alkylamino and C 1-8  dialkylamino; R 3  is selected from the group consisting of hydrogen, F, Cl, Br, I, \u2014CN, C 1-8  alkyl and C 1-8  haloalkyl; R 4  is selected from the group consisting of hydrogen, C 1-4  alkyl and C 1-4  haloalkyl; or R 1  and R 4  are combined to form a 3- to 7-membered heterocycle ring as described above; R 5  is selected from the group consisting of F, Cl, Br, I, \u2014CN, C 1-8  alkyl, C 1-8  haloalkyl, C 1-8  alkoxy, C 3-8  cycloalkyl and C 2-7  heterocyclyl, wherein said C 3-8  cycloalkyl and C 2-7  heterocyclyl is optionally substituted with 1-3 substituents selected from F, Cl, Br, I, \u2014OH, \u2014NH 2 , \u2014NH(C 1-4  alkyl)-, \u2014N(C 1-4  dialkyl)-, and C 1-4  alkyl substituted with 1-3 substituents selected from F, Cl, Br, I, \u2014OH, \u2014NH 2 , \u2014NH(C 1-4  alkyl)- and \u2014N(C 1-4  dialkyl)-; L is C 1-6  alkylene, wherein L is optionally substituted with from 1 to 3 substituents selected from the group consisting of C 1-4  alkyl, C 1-4  alkoxy, halo, oxo (\u2550O), and C 1-4  haloalkyl, and wherein any two substituents attached to the same atom on L are optionally combined to form a 3- to 5-membered carbocyclic ring; the subscript m represents the integer 0 or 1; X 1  and X 2  are each independently selected from the group consisting of absent, \u2014S\u2014, \u2014O\u2014 and \u2014N(R X )\u2014 wherein R x  is H, C 1-8  alkyl, C 1-8  haloalkyl, and wherein if the subscript m is 0 then one of X 1  or X 2  is absent; the ring \u201cA\u201d in is selected from the group consisting of: (i) C 2-11  heterocycle comprising a nitrogen atom and further optionally comprising 1-2 heteroatoms selected from N, O and S; wherein\n R AA  is independently selected from the group consisting of C 1-8  alkyl, C 1-8  haloalkyl, C 1-8  heteroalkyl, F, Cl, Br, I, \u2014CN, \u2014(X RAA ) 0-1 NR AA1 R AA2 , \u2014(X RAA ) 0-1 OR AA1 , \u2014(X RAA ) 0-1 SR AA1 , \u2014(X RAA ) 0-1 N(R AA1 )C(\u2550O)OR AA3 , \u2014(X RAA ) 0-1 OC(\u2550O)N(R AA1 )(R AA2 ), \u2014(X RAA ) 0-1 N(R AA1 )C(\u2550O)N(R AA1 )(R AA2 ), \u2014(X RAA ) 0-1 C(\u2550O)N(R AA1 )(R AA2 ), \u2014(X RAA ) 0-1 N(R AA1 )C(\u2550O)R AA2 , \u2014(X RAA ) 0-1 C(\u2550O)OR AA1 , \u2014(X RAA ) 0-1 OC(\u2550O)R AA1 , \u2014(X RAA ) 0-1 S(O) 1-2 R AA3 , \u2014(X RAA ) 0-1 S(O) 1-2 N(R AA1 )(R AA2 ), \u2014(X RAA ) 0-1 N(R AA1 )S(O) 1-2 N(R AA1 )(R AA2 ), (X RAA ) 0-1 N(R AA1 )S(O) 1-2 (R AA3 ), and \u2014C(\u2550O)R AA1 ; wherein X RAA  is selected from the group consisting of absent, C 1-4  alkylene, C 1-4  heteroalkylene, C 2-4  alkenylene and C 2-4  alkynylene; X RAA  is optionally substituted with 1 to 3 substituents selected from the group consisting of C 1-4  alkyl, C 1-4  haloalkyl, C 1-4  heteroalkyl and oxo (\u2550O); R AA1  and R AA2  are each independently selected from the group consisting of hydrogen, C 1-8  alkyl, C 2-8  alkenyl and C 1-8  haloalkyl; R AA3  is selected from the group consisting of C 1-8  alkyl, C 2-8  alkenyl and C 1-8  haloalkyl; wherein R AA  substituent is optionally substituted with from 1 to 5 R RAA  substituents selected from, F, Cl, Br, I, \u2014NH 2 , \u2014OH, \u2014CN, \u2014NO 2 , \u2550O, C 1-4  alkyl, C 1-4  haloalkyl, C 1-4  alkoxy, C 1-4  alkylamino and C 1-4  dialkylamino; \n n is an integer from 0 to 5; \n R A  is selected from the group consisting of \u2014(C\u2550O)OR A1 , (C 6-10  aryl) 1-2 -(X RA )\u2014, (5- to 10-membered heteroaryl) 1-2 -(X RA )\u2014, (C 3-12  cycloalkyl) 1-2 -(X RA )\u2014, and (C 2-11  heterocyclyl) 1-2 -(X RA )\u2014, wherein said C 6-10  aryl, 5- to 10 membered heteroaryl, C 3-12  cycloalkyl and C 2-11  heterocyclyl of R A  is independently optionally substituted with from 1 to 5 R RA  substituents selected from the group consisting of F, Cl, Br, I, \u2014NH 2 , \u2014OH, \u2014CN, \u2014NO 2 , \u2550O, C 1-4  alkyl, C 1-4  haloalkyl, C 1-4  alkoxy, C 1-4  alkylamino, C 1-4  dialkylamino, \u2014N(R A1 )C(\u2550O)OR A3 , \u2014OC(\u2550O)N(R A1 )(R A1 ), \u2014N(R A1 )C(\u2550O)N(R A1 )(R A2 ), \u2014C(\u2550O)N(R A1 )(R A2 ), \u2014N(R A1 )C(\u2550O)R A2 , \u2014C(\u2550O)OR A1 , \u2014C(\u2550O)OR A1 , \u2014OC(\u2550O)R A1 , \u2014S(O) 1-2 R A3 , \u2014S(O) 1-2 N(R A1 )(R A2 ), \u2014N(R A1 )S(O) 1-2 N(R A1 )(R A2 ), \u2014N(R A1 )S(O) 1-2 (R A3 ), \u2014C(\u2550O)R A1 , C 3-6  cycloalkyl, C 3-6  cycloalkoxy, C 2-5  heterocyclyl, C 2-5  heterocyclyloxy, 5- to 6 membered heteroaryl and phenyl, wherein the R RA  substituent is optionally substituted with 1 to 5 R RAi  substituents selected from, F, Cl, Br, I, \u2014NH 2 , \u2014OH, \u2014CN, \u2014NO 2 , C 1-4  alkyl, C 1-4  haloalkyl, C 1-4  alkoxy, C 1-4 (halo)alkoxy, C 1-4  alkylamino and C 1-4  dialkylamino; X RA  is selected from the group consisting of absent, \u2014O\u2014, \u2014S\u2014, \u2014N(H)\u2014, \u2014N(C 1-4  alkyl)-, \u2014S(O) 1-2 \u2014, \u2014S(O) 1-2 N(H)\u2014, \u2014C(C\u2550O)N(H)\u2014, \u2014C(C\u2550O)N(C 1-4  alkyl)-, \u2014OC(C\u2550O)N(H)\u2014, \u2014N(H)C(C\u2550O)N(H)\u2014, \u2014N(H)S(O) 1-2 N(H)\u2014, \u2014C(\u2550O)\u2014, C 1-4  alkylene, C 1-4  heteroalkylene, C 2-4  alkenylene and C 2-4  alkynylene; wherein X RA  is optionally substituted with 1 to 3 substituents selected from the group consisting of C 1-4  alkyl, C 1-4  haloalkyl, C 1-4  heteroalkyl and oxo (\u2550O); R A1  and R A2  are each independently selected from the group consisting of hydrogen, C 1-8  alkyl, C 2-8  alkenyl, C 1-8  haloalkyl, C 3-8  cycloalkyl, phenyl, benzyl, 5- to 6-membered heteroaryl and C 2-7  heterocyclyl; R A3  is selected from the group consisting of C 1-8  alkyl, C 2-8  alkenyl, C 1-8  haloalkyl, C 3-8  cycloalkyl, phenyl, benzyl, 5- to 6-membered heteroaryl and C 2-7  heterocyclyl; and \n q is an integer from 0 to 1; \n (ii) C 3-12  membered carbocycle; wherein\n R A  is selected from the group consisting of C 1-8  alkyl, C 1-8  alkoxy, C 1-8  alkylamino, C 1-8  dialkylamino, C 1-8  haloalkyl, F, Cl, Br, I, \u2014OH, \u2014CN, \u2014NO 2 , \u2550O, \u2014(X RA ) 0-1 NR A1 R A2 , \u2014(X RA ) 0-1 OR A1 , \u2014(X RA ) 0-1 SR A1 , \u2014(X RA ) 0-1 N(R A1 )C(\u2550O)OR A3 , \u2014(X RA ) 0-1 OC(\u2550O)N(R A1 )(R A2 ), \u2014(X RA ) 0-1 N(R A1 )C(\u2550O)N(R A1 )(R A2 ), \u2014(X RA ) 0-1 C(\u2550O)N(R A1 )(R A2 ), \u2014(X RA ) 0-1 N(R A1 )C(\u2550O)R A2 , \u2014(X RA ) 0-1 C(\u2550O)OR A1 , \u2014(X RA ) 0-1 OC(\u2550O)R A1 , \u2014(X RA ) 0-1 S(O) 1-2 R A3 , \u2014(X RA ) 0-1 S(O) 1-2 N(R A1 )(R A2 ), \u2014(X RA ) 0-1 N(R A1 )S(O) 1-2 N(R A1 )(R A2 ), (X RA ) 0-1 N(R A1 )S(O) 1-2 (R A3 ), \u2014C(\u2550O)R A1 , C 3-6  cycloalkyl, C 2-5  heterocyclyl, 5- to 10 membered heteroaryl and phenyl; wherein X RA  is selected from the group consisting of C 1-4  alkylene, C 1-4  heteroalkylene, C 2-4  alkenylene and C 2-4  alkynylene; wherein R A1  and R A2  are independently selected from the group consisting of hydrogen, C 1-8  alkyl, C 2-8  alkenyl, C 1-8  haloalkyl, C 3-8  cycloalkyl, phenyl, benzyl, 5- to 6 membered heteroaryl and C 2-7  heterocyclyl; R A3  is selected from the group consisting of C 1-8  alkyl, C 1-8  haloalkyl, C 3-8  cycloalkyl, phenyl, benzyl, 5- to 6-membered heteroaryl and C 2-7  heterocyclyl; wherein R A  substituent is optionally substituted with from 1 to 5 R RA  substituents selected from, F, Cl, Br, I, \u2014NH 2 , \u2014OH, \u2014CN, \u2014NO 2 , \u2550O, C 1-4  alkyl, C 1-4  haloalkyl, C 1-4  alkoxy, C 1-4  alkylamino and C 1-4  dialkylamino; \n n is the integer 0; and \n q is the integer 0 to 6; \n (iii) phenyl substituted at the 2-position, the 3,4-positions, the 2,4-positions, or the 3,5-positions with groups independently selected from R A , wherein each\n R A  is selected from the group consisting of C 1-8  alkyl, C 1-8  alkoxy, C 1-8  alkylamino, C 1-8  dialkylamino, C 1-8  haloalkyl, F, Cl, Br, I, \u2014OH, \u2014CN, \u2014NO 2 , \u2550O, \u2014(X RA ) 0-1 NR A1 R A2 , \u2014(X RA ) 0-1 OR A1 , \u2014(X RA ) 0-1 SR A1 , \u2014(X RA ) 0-1 N(R A1 )C(\u2550O)OR A3 , \u2014(X RA ) 0-1 OC(\u2550O)N(R A1 )(R A2 ), \u2014(X RA ) 0-1 N(R A1 )C(\u2550O)N(R A1 )(R A2 ), \u2014(X RA ) 0-1 C(\u2550O)N(R A1 )(R A2 ), \u2014(X RA ) 0-1 N(R A1 )C(\u2550O)R A2 , \u2014(X RA ) 0-1 C(\u2550O)OR A1 , \u2014(X RA ) 0-1 OC(\u2550O)R A1 , \u2014(X RA ) 0-1 S(O) 1-2 R A3 , \u2014(X RA ) 0-1 S(O) 1-2 N(R A1 )(R A2 ), \u2014(X RA ) 0-1 N(R A1 )S(O) 1-2 N(R A1 )(R A2 ), \u2014(X RA ) 0-1 N(R A1 )S(O) 1-2 (R A3 ), \u2014C(\u2550O)R A1 , C 3-6  cycloalkyl, C 3-6  cycloalkoxy, C 2-5  heterocyclyl, C 2-5  heterocycloalkoxy, 5- to 10 membered heteroaryl and phenyl; wherein X RA  is selected from the group consisting of C 1-4  alkylene, C 1-4  heteroalkylene, C 2-4  alkenylene and C 2-4  alkynylene; wherein R A1  and R A2  are independently selected from the group consisting of hydrogen, C 1-8  alkyl, C 2-8  alkenyl, C 1-8  haloalkyl, C 3-8  cycloalkyl, phenyl, benzyl, 5- to 6-membered heteroaryl and C 2-7  heterocyclyl; R A3  is selected from the group consisting of C 1-8  alkyl, C 1-8  haloalkyl, C 3-8  cycloalkyl, phenyl, benzyl, 5- to 6-membered heteroaryl and C 2-7  heterocyclyl; wherein R A  substituent is optionally substituted with from 1 to 5 R RA  substituents selected from, F, Cl, Br, I, \u2014NH 2 , \u2014OH, \u2014CN, \u2014NO 2 , \u2550O, C 1-4  alkyl, C 1-4  haloalkyl, C 1-4  alkoxy, C 1-4  alkylamino, C 1-4  dialkylamino, C 2-5  heterocyclyloxy, and C 2-7  heterocyclyl that is optionally substituted with one or more substituents independently selected from, F, Cl, Br, I, \u2014NH 2 , \u2014OH, \u2014CN, \u2014NO 2 , \u2550O, C 1-4  alkyl, C 1-4  haloalkyl, C 1-4  alkoxy, and C 1-4  alkoxycarbonyl; \n (iv) naphthyl; and (v) 5- to 10-membered heteroaryl comprising 1- to 3-nitrogen atoms and optionally further comprising 1- to 2-heteroatoms selected from O and S; wherein in (iv) and (v)\n R A  is selected from the group consisting of C 1-8  alkyl, C 1-8  alkoxy, C 1-8  alkylamino, C 1-8  dialkylamino, C 1-8  haloalkyl, F, Cl, Br, I, \u2014OH, \u2014CN, \u2014NO 2 , \u2550O, \u2014(X RA ) 0-1 NR A1 R A2 , \u2014(X RA ) 0-1 OR A1 , \u2014(X RA ) 0-1 SR A1 , \u2014(X RA ) 0-1 N(R A1 )C(\u2550O)OR A3 , \u2014(X RA ) 0-1 OC(\u2550O)N(R A1 )(R A1 ), \u2014(X RA ) 0-1 N(R A1 )C(\u2550O)N(R A1 )(R A2 ), \u2014(X RA ) 0-1 C(\u2550O)N(R A1 )(R A2 ), \u2014(X RA ) 0-1 N(R A1 )C(\u2550O)R A2 , \u2014(X RA ) 0-1 C(\u2550O)OR A1 , \u2014(X RA ) 0-1 OC(\u2550O)R A1 , \u2014(X RA ) 0-1 S(O) 1-2 R A3 , \u2014(X RA ) 0-1 S(O) 1-2 N(R A1 )(R A2 ), \u2014(X RA ) 0-1 N(R A1 )S(O) 1-2 N(R A1 )(R A2 ), \u2014(X RA ) 0-1 N(R A1 )S(O) 1-2 (R A3 ), \u2014C(\u2550O)R A1 , C 3-6  cycloalkyl, C 2-5  heterocyclyl, 5- to 10 membered heteroaryl and phenyl; wherein X RA  is selected from the group consisting of C 1-4  alkylene, C 1-4  heteroalkylene, C 2-4  alkenylene and C 2-4  alkynylene; wherein R A1  and R A2  are independently selected from the group consisting of hydrogen, C 1-8  alkyl, C 2-8  alkenyl, C 1-8  haloalkyl, C 3-8  cycloalkyl, phenyl, benzyl, 5- to 6 membered heteroaryl and C 2-7  heterocyclyl; R A3  is selected from the group consisting of C 1-8  alkyl, C 1-8  haloalkyl, C 3-8  cycloalkyl, phenyl, benzyl, 5- to 6-membered heteroaryl and C 2-7  heterocyclyl; wherein R A  substituent is optionally substituted with from 1 to 5 R RA  substituents selected from, F, Cl, Br, I, \u2014NH 2 , \u2014OH, \u2014CN, \u2014NO 2 , \u2550O, C 1-4  alkyl, C 1-4  haloalkyl, C 1-4  alkoxy, C 1-4  alkylamino, C 1-4  dialkylamino and C 2-5  heterocyclyloxy; \n n is the integer 0; and \n q is an integer from 0 to 4.

Metadata:
- Claim Count in Document: 37.0
- Percentile: 97.0
- Lexical Diversity: 1.7551
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15321335', '15988956', '14772735', '14772726', '13899469']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8168065316405423
- 35 USC 102 Novelty (BERT): 0.5962502302953017
- Combined Prediction Score: 0.7947509015060182
- Mean Citation Score: 460.31907999999993
- Max Citation Score: 530.8615
- Similarity Product: 470.6935835937262

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test